4//SEC Filing
KARSEN PERRY A 4
Accession 0001209191-20-064425
CIK 0001652130other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:29 PM ET
Size
25.0 KB
Accession
0001209191-20-064425
Insider Transaction Report
Form 4
KARSEN PERRY A
Director
Transactions
- Exercise/Conversion
Common Stock
2020-12-17$25.98/sh+19,000$493,620→ 74,764 total - Exercise/Conversion
Common Stock
2020-12-17$15.78/sh+19,000$299,820→ 93,764 total - Sale
Common Stock
2020-12-17$52.52/sh−21,978$1,154,285→ 71,786 total - Exercise/Conversion
Stock Option (right to buy)
2020-12-17−19,000→ 0 totalExercise: $14.35Exp: 2027-05-17→ Common Stock (19,000 underlying) - Exercise/Conversion
Common Stock
2020-12-17$14.35/sh+19,000$272,650→ 55,764 total - Sale
Common Stock
2020-12-17$53.69/sh−45,450$2,440,211→ 26,336 total - Exercise/Conversion
Stock Option (right to buy)
2020-12-17−19,000→ 0 totalExercise: $25.98Exp: 2028-05-16→ Common Stock (19,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2020-12-17−19,000→ 0 totalExercise: $15.78Exp: 2029-05-20→ Common Stock (19,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2020-12-17−31,764→ 0 totalExercise: $18.00Exp: 2026-05-04→ Common Stock (31,764 underlying) - Exercise/Conversion
Common Stock
2020-12-17$18.00/sh+31,764$571,752→ 36,764 total - Sale
Common Stock
2020-12-17$54.33/sh−21,336$1,159,185→ 5,000 total
Footnotes (8)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.02 to $53.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2020 at each separate price.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.09 to $54.08, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2020 at each separate price.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.10 to $54.48, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2020 at each separate price.
- [F5]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 5, 2019.
- [F6]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 17, 2018.
- [F7]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 17, 2019.
- [F8]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 21, 2020.
Documents
Issuer
Intellia Therapeutics, Inc.
CIK 0001652130
Entity typeother
Related Parties
1- filerCIK 0001260573
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 4:29 PM ET
- Size
- 25.0 KB